首页> 外文期刊>Hong Kong Journal of Paediatrics >Evaluation of the 18-month 'Pilot Study of Newborn Screening for Inborn Errors of Metabolism' in Hong Kong The Task Force on the Pilot Study of Newborn Screening for Inborn Errors of Metabolism
【24h】

Evaluation of the 18-month 'Pilot Study of Newborn Screening for Inborn Errors of Metabolism' in Hong Kong The Task Force on the Pilot Study of Newborn Screening for Inborn Errors of Metabolism

机译:评价香港香港新生儿筛查试验研究中新生儿筛查试验研究的18个月“新生儿筛查试验研究”的18个月“试验研究”

获取原文
       

摘要

Introduction: After the release of the Chief Executive's 2015 Policy Address in Hong Kong, a pilot study was planned and implemented to study the feasibility of trying out in the public healthcare system a screening programme for newborn babies for inborn errors of metabolism (IEM). After six months of preparation, the "Pilot Study of Newborn Screening for Inborn Errors of Metabolism" was launched in October 2015 in two public birthing hospitals (Queen Elizabeth Hospital and Queen Mary Hospital). It lasted for 18 months in two phases: Phase I from October 2015 to March 2016 (covering 21 IEM diseases) and Phase II from April 2016 to March 2017 (covering totally 24 IEM diseases). Aim: This paper is to review the course of events and discuss about the clinical findings of the Pilot Study. Results and conclusion: The Pilot Study had been operated smoothly, in aspects of parental education, specimen collection, preparation and dispatch of specimens. There were effective communication and cooperation among different parties involved in baby recall, arrangement of further investigations and clinical management. 15,138 out of 15,361 (98.5%) eligible babies had parental written consents to join the Pilot Study and 9 IEM cases were confirmed (incidence of the Pilot Study was 1 in 1,682 (Confidence interval (CI): one in 909 to one in 3,333)). Two mothers were incidentally picked up with IEM of carnitine uptake deficiency (CUD) and classic phenylketonuria respectively, and two false negative cases of Citrullinaemia type II (CIT type II) were notified. Incidence was increased to 1 in 1,376 if the two false negative cases were also included and it is higher than those in other countries or regions. Collectively, IEM cannot be claimed to be rare in Hong Kong.
机译:介绍:在香港首席执行官2015年施政报告发布后,计划并实施了一项试点研究,研究了在公共医疗保健系统中尝试的可行性,为新生儿婴儿出于原始新陈代谢(IEM)。在六个月的准备后,2015年10月在两家公共分娩医院(女王伊丽莎白医院和女王玛丽医院)推出了“新生儿筛查的新生儿筛查试验研究”。它以两阶段持续了18个月:第一阶段2015年10月至2016年3月(涵盖21次IEM疾病)和第二阶段2016年4月至2017年3月(共24例IEM疾病)。目的:本文是审查事件课程,讨论试验研究的临床调查结果。结果与结论:在父母教育,标本收集,标本的方面,试验研究顺利进行了顺利。婴儿回忆中的不同方面有效的沟通与合作,进一步调查和临床管理的安排。 15,138人中为15,361名(98.5%)符合条件的婴儿的父母书面同意加入试点研究,并确认了9个IEM案件(试点研究的发生率为1,682(CI):909中的一个人:3,333中的一个)。两名母亲分别偶然地挑选了肉碱吸收缺损(CUD)和经典苯丙酮尿的IEM,并通知了两个假阴性患有II型的假阴性病例(CIT II类)。如果还包括两个错误的阴性案件,则发病率增加到1,376中,并且它高于其他国家或地区。集体,IEM不能声称在香港罕见。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号